FindTrial
Sign In

CS1001

DRUG7 trials

Sponsors

CStone Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Conditions

Advanced CancerAdvanced Refractory Solid TumorsAdvanced Solid TumorAdvanced Solid TumorsExtranodal Natural Killer/T-Cell LymphomaHodgkin LymphomaRelapsed Small Cell Lung Cancer

Phase 1

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
CompletedNCT03312842
CStone PharmaceuticalsAdvanced Cancer
Start: 2017-10-19End: 2022-02-16Updated: 2022-05-26
A Study of CS1001 in Subjects with Advanced Solid Tumors
CompletedNCT03744403
CStone PharmaceuticalsAdvanced Solid Tumors
Start: 2018-12-04End: 2021-07-21Updated: 2024-09-19
A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
CompletedNCT04200404
CStone PharmaceuticalsAdvanced Refractory Solid Tumors
Start: 2019-12-13End: 2021-08-18Updated: 2022-05-06
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
CompletedNCT04421352
CStone PharmaceuticalsRelapsed Small Cell Lung Cancer
Start: 2021-01-12End: 2023-12-22Updated: 2024-03-07
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
NCT04472858
Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor
Start: 2020-10-15End: 2023-12-31Target: 30Updated: 2022-11-29

Phase 2

A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
CompletedNCT03505996
CStone PharmaceuticalsHodgkin Lymphoma
Start: 2018-05-22End: 2021-11-01Updated: 2022-10-31
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
CompletedNCT03595657
CStone PharmaceuticalsExtranodal Natural Killer/T-Cell Lymphoma
Start: 2018-06-12End: 2023-03-20Updated: 2024-06-18

Related Papers

GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).
Journal of Clinical Oncology2022-06-016 citations
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
2022-01-0513 citations
Platinum-based chemotherapy (chemo) with CS1001, an anti-PD-L1 antibody, for first-line advanced non-small cell lung cancer (NSCLC): Preliminary results from phase Ib cohorts of CS1001-101 study.
Journal of Clinical Oncology2020-05-20
Gemstone-301: A phase III clinical trial of CS1001 as consolidation therapy in subjects with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who have not progressed after prior concurrent/sequential chemoradiotherapy (CRT).
Journal of Clinical Oncology2019-05-202 citations
A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
Journal of Clinical Oncology2019-05-201 citations
Preliminary safety, pharmacokinetics (PK) and efficacy results from a phase I study of CS1001, an anti-programmed death ligand-1 (PD-L1) monoclonal antibody (mAb) in patients (pts) with advanced tumors
Annals of Oncology2018-10-012 citations